Clozapine and Fever: A Case of Continued Therapy with Clozapine

Clinical Neuropharmacology

Volumn 38, Issue 4, 2015, Pages 151-153

  Bruno, Valentina ^a   Valiente Gómez, Alicia ^b,c,d   Alcoverro, Oscar ^a  

^a HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^b Benito Menni Complex Assistencial en Salut Mental   (Spain)

^c FIDMAG GERMANES HOSPITALÀRIES RESEARCH FOUNDATION   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

Author keywords

clozapine; schizoaffective disorder

Indexed keywords

CLOZAPINE; CREATINE KINASE; PARACETAMOL; NEUROLEPTIC AGENT;

ADULT; AGRANULOCYTOSIS; ARTICLE; ASPIRATION PNEUMONIA; CASE REPORT; DISEASE SEVERITY; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; ILEUS; IMMUNOMODULATION; INFECTION; LEUKOCYTOSIS; MALE; MIDDLE AGED; MYOCARDITIS; NASOPHARYNGEAL ASPIRATION; NEGATIVE SYNDROME; NEUROLEPTIC MALIGNANT SYNDROME; NEUTROPENIA; POSITIVE SYNDROME; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SIDE EFFECT; TACHYCARDIA; WEIGHT GAIN; BIPOLAR DISORDER; CHEMICALLY INDUCED; COMPLICATION; FEVER; PSYCHOTIC DISORDERS;

ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CLOZAPINE; FEVER; HUMANS; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS;

EID: 84938303322     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0000000000000088     Document Type: Article

References (12)

1. Patel SS, Allin MP,. Physical complications in early clozapine treatment: a case report and implications for safe monitoring. Ther Adv Psychopharmacol 2011; 1 (1): 25-29.
2. Oerther S, Ahlenius S,. Atypical antipsychotics and dopamine D(1) receptor agonism: an in vivo experimental study using core temperature measurements in the rat. J Pharmacol Exp Ther 2000; 292 (2): 731-736.
3. Bruijnzeel D, Suryadevara U, Tandon R,. Antipsychotic treatment of schizophrenia: an update. Asian J Psychiatr 2014; 11: 3-7.
4. Lowe CM, Grube RR, Scates AC,. Characterization and clinical management of clozapine-induced fever. Ann Pharmacother 2007; 41 (10): 1700-1704.
5. Jeong SH, Ahn YM, Koo YJ, The characteristics of clozapine-induced fever. Schizophr Res 2002; 56 (1-2): 191-193.
6. Young CR, Bowers MB Jr, Mazure CM,. Management of the adverse effects of clozapine. Schizophr Bull 1998; 24 (3): 381-390.
7. Kohen I, Afzal N, Hussain S, Increases in C-reactive protein may predict recurrence of clozapine-induced fever. Ann Pharmacother 2009; 43 (1): 143-146.
8. Tham JC, Dickson RA,. Clozapine-induced fevers and 1-year clozapine discontinuation rate. J Clin Psychiatry 2002; 63 (10): 880-884.
9. Nielsen J, Correll CU, Manu P, Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? J Clin Psychiatry 2013; 74 (6): 603-613. quiz 613.
10. Pui-yin Chung J, Shiu-yin Chong C, Chung KF, The incidence and characteristics of clozapine-induced fever in a local psychiatric unit in Hong Kong. Can J Psychiatry 2008; 53 (12): 857-862.
11. Tremeau F, Clark SC, Printz D, Spiking fevers with clozapine treatment. Clin Neuropharmacol 1997; 20 (2): 168-170.
12. Martin N, Williams R,. Management of clozapine-induced fever: a case of continued therapy throughout fever. J Psychiatry Neurosci 2013; 38 (4): E9-E10.